Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women

International Journal of Clinical Pharmacology Research

Volumn 21, Issue 1, 2001, Pages 31-41

  Mirkin, A ^a   Mas, R ^a   Martinto, M ^a   Boccanera, R ^a   Robertis, A ^a   Poudes, R ^a   Fuster, A ^a   Lastreto, E ^a   Yanez M ^a   Irico, G ^a   McCook, B ^a   Farre A ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MIDDLE AGED; POSTMENOPAUSE;

EID: 0034774685     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. The epidemiology of cardiovascular disease in postmenopausal women
2. Menopause and heart disease: A review
3. Cardiovascular disease in women
4. Review: Estrogen replacement therapy and cardiovascular protection: Lipid mechanisms are the tip of an iceberg
5. Prevalence of high blood cholesterol among US adults: An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel
6. Management of postmenopausal women who have hyperlipidemia
7. Cholesterol and heart disease in older persons and women: Review of an NHLBI workshop
8. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
9. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension
10. Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women
11. Menopause estrogen and risk for coronary heart disease
12. Changes in lipids and lipoproteins with long-term estrogen deficiency and hormone replacement therapy
13. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins
14. Hypercholesterolemia in postmenopausal women: Metabolic defects and response to low dose lovastatin
15. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women
16. Comparison of the effects of simvastatin versus hormone replacement therapy in the treatment of postmenopausal women with primary hypercholesterolemia
17. A comparison of estrogen replacement, pravastatin and combined treatment for the management of hypercholesterolemia in postmenopausal women
18. Concurrent use of simvastatin and estrogen-progastin therapy compared with each therapy alone for hypercholesterolemia in postmenopausal women
19. Current and future treatment of hyperlipidemia: The role of statins
20. Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblasts
21. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolemia induced by a wheat starch-casein diet
22. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment
23. Effect of policosanol in lowering-cholesterol levels in patients with type II hypercholesterolemia
24. One-year study of the efficacy and safety of policosanol (5 mg twice daily) in the treatment of type II hypercholesterolemia
25. A two year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinemia
26. The efficacy and toff erability of policosanol (10 mg/day) in elderly patients with type II hyperlipoproteinemia: A one-year study
27. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia
28. A comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia
29. A long-term open study of the efficacy and tolerability of policosanol in patients with high global coronary risk
30. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors
31. Treatment of hypercholesterolemia in NIDDM with policosanol
32. Effect of policosanol on patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia: A pilot study
33. A double-blind placebo-controlled study of the effects of policosanol in patients with intermittent claudication
34. Effect of policosanol on postmenopausal women with type II hypercholesterolemia
35. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals
36. Separation of serum high-density lipoprotein for cholesterol determination: Ultracentrifugation vs. precipitation with sodium phosphotungstate and magnesium chloride
37. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge
38. Effects of policosanol on platelet aggregation in rats
39. Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers
40. Effect of policosanol on platelet aggregation in healthy volunteers
41. Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers
42. Comparative study of policosanol, aspirin and the combination of policosanol-aspirin on platelet aggregation in healthy volunteers
43. Effect of policosanol on in vivo and in vitro rat liver microsomal lipid peroxidation
44. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro
45. Effect of policosanol in circulating endothelial cell in experimental models in Sprague- Dawley rats and in rabbits